Brief: Lisata Therapeutics Announces First Patient Treated In Bolster Trial Of Lsta1, A Novel Tumor-Targeting And Penetrating Peptide, In Patients With Advanced Solid Tumors
12/09/2023 14:32
Sept 12 (Reuters) - Lisata Therapeutics Inc LSTA.O :
* LISATA THERAPEUTICS ANNOUNCES FIRST PATIENT TREATED IN
BOLSTER
TRIAL OF LSTA1, A NOVEL TUMOR-TARGETING AND PENETRATING PEPTIDE,
IN PATIENTS WITH ADVANCED SOLID TUMORS
Source text for Eikon: ID:nGNXcdgnKb
Further company coverage: LSTA.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Lisata Therapeutics
See all newsBrief: Lisata Therapeutics - Amends Merger Offer Price To $4 Per Share Plus CVR
Brief: Lisata Therapeutics Enters Into Definitive Agreement To Be Acquired By Kuva Labs, Inc.
U.S. STOCKS ON THE MOVE-Oklo, AMD, Lam Research
U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies
Lisata jumps as Kuva Labs strikes acquisition deal